Compare MGM Resorts International (MGM) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Moderna, Inc. — how do they compare? MGM Resorts International trades at $29.27 (market cap $7.55B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 10.4× MGM Resorts International's market cap, and MGM Resorts International pays a 0.03% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 91 Days and Moderna, Inc. for 59 Days on average.
| MGM | MRNA | |
|---|---|---|
Market Cap | $7.55B | $78.65B |
Volume | 5,342,346 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $203.46 |
52-Week Low | $30.00 | $22.36 |
Typical Hold Time | 91 Days | 59 Days |
Enterprise Value | $34.85B | $74.80B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $30.01, showing minimal daily movement (+0.03%) amid recent volatility following the collapse of Barry Diller's $48.30 per share acquisition proposal. The stock faces bearish technical signals with oversold RSI readings, while fundamentals show mixed results with Q2 2026 earnings beating expectations but net margins declining to 2.4% in 2025. Recent news highlights potential MGM interest in acquiring People Inc., creating uncertainty around strategic direction.
MGM presents a value opportunity with P/S ratio of 0.45 below industry averages, supported by strong analyst consensus ($48.75 price target, 51% buy ratings). However, risks include declining profit margins, failed acquisition attempts, and ongoing debt burden. The stock's current discount to analyst targets suggests potential upside if operational improvements materialize.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
